Home Ingredients FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives)
Menopause SupportWomen's Health

FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives)

Trigonella foenum-graecum
Evidence Level
Strong
2 Clinical Trials
6 Documented Benefits
4/5 Evidence Score

FenuSmart® (also spelled FenuSMART™) is Akay Bioactives' standardized fenugreek (Trigonella foenum-graecum) husk extract — featuring a unique 3:1 (w/w) ratio of protodioscin to trigonelline (saponin and alkaloid bioactives). Supported by 5 clinical studies and 2 US patents. The flagship trial (Shamshad Begum 2016, Phytotherapy Research, PMID 27406028) randomized 88 women with moderate-severe postmenopausal symptoms to 1,000 mg/day FenuSmart vs placebo for 90 days. Outcomes vs baseline/placebo: 120% increase in plasma estradiol (p<0.01); 32% of subjects reported NO hot flashes after supplementation; remaining subjects reduced from 3-5 hot flashes/day to 1-2; hot flash severity reduced 47.8%; night sweats reduced 53%; mood swings 69%; sleeplessness 71%; irritability 76%; apprehensiveness 60%; headaches 46%; vaginal dryness 56.3%. Subsequent 2020 trial (PharmaNutrition, n=48) validated efficacy at lower 250 mg × 2/day (500 mg/day) dose for 6 weeks. Honest framing: substantial clinical evidence base for menopausal symptom support, with the estradiol elevation mechanism distinguishing FenuSmart from purely phytoestrogen-based menopause supplements. Akay-funded but published in peer-reviewed journals.

Studied Dose Primary clinical dose: 1,000 mg/day FenuSmart for 90 days (Shamshad Begum 2016 trial). Lower-dose protocol: 250 mg × 2/day (500 mg/day total) for 6 weeks (2020 PharmaNutrition trial) — also showed efficacy at this lower dose. Choose dose based on symptom severity and individual response. Effects on hot flashes and estradiol measurable within weeks; full quality-of-life improvements over 12 weeks.
Active Compound Trigonella foenum-graecum (fenugreek) husk extract standardized to protodioscin and trigonelline at 3:1 (w/w) ratio. Produced via patented extraction process. Bioactive families: steroidal saponins (protodioscin and related furostanol saponins) and alkaloids (trigonelline). The protodioscin/trigonelline ratio is the specification target distinguishing FenuSmart from generic fenugreek extracts.

Benefits

120% increase in plasma estradiol (Shamshad Begum 2016)

Randomized double-blind placebo-controlled trial in 88 women with moderate-severe postmenopausal symptoms: 1,000 mg/day FenuSmart for 90 days increased plasma estradiol by 120% (p<0.01) vs baseline and placebo. From 131.22 to 288.46 pmol/L mean values. Critical mechanism distinguishing FenuSmart — actual endogenous estradiol elevation rather than just symptomatic relief or phytoestrogen activity. Published in Phytother Res 2016.

Supported by Trial 1

Hot flash reduction (47.8% severity, 32% elimination)

Same trial: 32% of subjects reported NO hot flashes after 90 days of FenuSmart supplementation. Remaining subjects reduced from 3-5 hot flashes/day at baseline to 1-2/day. Overall hot flash severity reduction: 47.8% vs placebo. Hot flashes are the most disruptive symptom for many menopausal women and a primary outcome for non-hormonal menopause therapies.

Supported by Trial 1, Trial 2

Sleep and mood improvements

Multi-symptom improvements documented: night sweats -53%, sleeplessness -71%, mood swings -69%, irritability -76%, apprehensiveness -60%, headaches -46%. Captures the constellation of menopausal symptoms beyond vasomotor events — recognizing that menopause affects sleep, mood, and cognition alongside hot flashes.

Supported by Trial 1

Vaginal moisture restoration

Vaginal dryness — a frequent and underreported menopausal symptom — decreased 56.3% in the FenuSmart group. Practical relevance for menopause-related sexual health and quality of life. Effect likely mediated by the estradiol elevation since vaginal tissue is highly estrogen-responsive.

Supported by Trial 1, Trial 2

Lipid profile maintenance

While the placebo group showed expected age/menopause-related increases in total cholesterol, LDL, and triglycerides, FenuSmart subjects maintained baseline lipid levels — suggesting plausible cardiovascular benefit. Important because menopause is associated with adverse lipid changes that increase cardiovascular risk.

Supported by Trial 1

Low-dose efficacy at 500 mg/day

2020 PharmaNutrition follow-up trial: 250 mg × 2/day (500 mg/day total) for 6 weeks in 48 post-menopausal women also produced significant menopausal symptom improvements. Allows lower-dose protocol for milder symptom profiles or budget-conscious formulations.

Supported by Trial 2

Mechanism of action

1

Endogenous estradiol elevation

Mechanism distinct from phytoestrogen activity (where the supplement binds estrogen receptors). FenuSmart's protodioscin appears to support endogenous estradiol synthesis — measured as 120% increase in plasma estradiol over 90 days. Likely operates via DHEA precursor pool support and/or aromatase pathway modulation.

2

Saponin/alkaloid synergy

The 3:1 protodioscin:trigonelline ratio is specification-controlled because the two bioactive classes appear to work synergistically — neither alone produces the full FenuSmart effect profile. This is why undefined fenugreek extracts produce variable clinical results across studies.

3

Vasomotor stability

Restored estradiol levels stabilize the hypothalamic thermoregulatory center, reducing the labile temperature setpoint that drives hot flashes and night sweats. Same downstream mechanism as hormone replacement therapy but via endogenous estradiol elevation rather than exogenous hormone administration.

4

Lipid metabolism support

Restored estradiol levels maintain favorable lipid profile (estrogen has well-established beneficial effects on HDL elevation and LDL reduction). Explains the FenuSmart group's stable lipid markers vs placebo group's expected adverse changes.

Clinical trials

1
FenuSmart 1,000 mg Menopause Trial — Shamshad Begum 2016

Randomized double-blind placebo-controlled trial in 88 women with moderate-severe postmenopausal symptoms (Greene Climacteric Scale, SF-36 quality-of-life testing). Intervention: 1,000 mg/day FenuSmart or placebo for 90 days. Outcomes: estradiol +120% (p<0.01); hot flashes eliminated in 32%; reduced 47.8% severity in remainder; night sweats -53%; mood swings -69%; sleeplessness -71%; irritability -76%; apprehensiveness -60%; headaches -46%; vaginal dryness -56.3%. Lipid profile maintained vs placebo deterioration. Published in Phytother Res 2016 (PMID 27406028).

2
FenuSmart Low-Dose Validation — 2020 PharmaNutrition

Randomized double-blind placebo-controlled trial in 48 post-menopausal women (average age 54). Intervention: 250 mg × 2/day (500 mg/day total) FenuSmart for 6 weeks. Outcomes: significant menopausal symptom improvements and hormonal balance support at this lower dose. DHEA (precursor to androgens and estrogens) elevation contributed to mechanism. Supports flexible dosing options for varying symptom severity profiles.

Side effects and drug interactions

Common Potential side effects

Well-tolerated in 90-day trial; no adverse hematological, biochemical, or clinical effects.
Maple-syrup body odor possible at high fenugreek doses (a characteristic fenugreek effect, harmless).
Possible mild GI effects (gas, bloating) at higher doses.
Fenugreek allergy contraindication — also cross-reacts with peanut and chickpea allergies in some individuals.
Pregnancy: AVOID — fenugreek is traditionally used to stimulate uterine activity and may pose miscarriage/preterm risk. Lactation: traditionally used as galactagogue but supplemental doses warrant clinician consultation.

Important Drug interactions

Anticoagulants — fenugreek contains coumarin-like compounds; monitor INR with warfarin.
Antidiabetic medications — fenugreek modestly lowers blood glucose; monitor and adjust diabetes medications.
Hormone replacement therapy — additive estrogenic effect; consult prescriber.
Hormone-sensitive conditions (estrogen receptor-positive breast cancer, endometriosis, fibroids) — caution due to estradiol-elevating mechanism.
Pregnancy: AVOID. Lactation: consult clinician despite traditional galactagogue use.
Featured In

Symptom-specific supplement guides

🌸Best Supplements for Menopause

More Menopause Support Ingredients

Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…
Cardiovascular
Flaxseed / Flaxseed Oil (Linum usitatissimum)
Flaxseed (linseed) is one of the richest plant sources of alpha-linolenic acid (ALA, omega…
Metabolic Health
Soy Isoflavones (Glycine max)
Soy isoflavones — primarily genistein, daidzein, and glycitein — are phytoestrogens found…
Menopause Support
Black Cohosh (Actaea racemosa)
Black cohosh is a flowering plant native to eastern North America whose root extract has b…

Explore Other Ingredients

Cognitive
Suntheanine®
Suntheanine® is a patented, 100% pure L-isomer theanine produced via an enzymatic process…
Sleep Health
Valerian Root
Valerian root is one of the most widely used herbal sleep aids in Western medicine, with a…
Cognitive
L-Theanine
L-Theanine, an amino acid primarily found in green tea (Camellia sinensis), is commonly su…

Frequently asked questions about FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives)

What is FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives)?

FenuSmart® (also spelled FenuSMART™) is Akay Bioactives' standardized fenugreek (Trigonella foenum-graecum) husk extract — featuring a unique 3:1 (w/w) ratio of protodioscin to trigonelline (saponin and alkaloid bioactives).

What does FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives) do?

Mechanism distinct from phytoestrogen activity (where the supplement binds estrogen receptors). FenuSmart's protodioscin appears to support endogenous estradiol synthesis — measured as 120% increase in plasma estradiol over 90 days. In clinical research, FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives) has been studied for 120% increase in plasma estradiol (shamshad begum 2016), hot flash reduction (47.8% severity, 32% elimination), sleep and mood improvements.

Who should take FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives)?

FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives) may be most relevant for people interested in menopause support, women's health. It has been clinically studied for 120% increase in plasma estradiol (shamshad begum 2016), hot flash reduction (47.8% severity, 32% elimination), sleep and mood improvements. As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives) take to work?

In clinical trials, effects have been measured at 6 weeks of consistent use. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives)?

FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives) can typically be taken with breakfast or dinner — taking with food reduces GI sensitivity for most supplements. Specific timing matters less than daily consistency for cumulative effects. Always check product labeling and follow personalized guidance from your healthcare provider.

Is FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives) worth taking?

FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives) has strong clinical evidence (Evidence Level 4/5 on NutraSmarts) for its primary uses, with multiple randomized controlled trials and meta-analyses supporting its benefits. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives) is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives)?

The clinically studied dose for FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives) is Primary clinical dose: 1,000 mg/day FenuSmart for 90 days (Shamshad Begum 2016 trial). Lower-dose protocol: 250 mg × 2/day (500 mg/day total) for 6 weeks (2020 PharmaNutrition trial) — also showed efficacy at this lower dose. Choose dose based on symptom severity and individual response. Effects on hot flashes and estradiol measurable within weeks; full quality-of-life improvements over 12 weeks.. Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives) used for?

FenuSmart® (Standardized Fenugreek Extract for Menopause — Akay Bioactives) is studied for 120% increase in plasma estradiol (shamshad begum 2016), hot flash reduction (47.8% severity, 32% elimination), sleep and mood improvements. Randomized double-blind placebo-controlled trial in 88 women with moderate-severe postmenopausal symptoms: 1,000 mg/day FenuSmart for 90 days increased plasma estradiol by 120% (p<0.01) vs baseline and placebo. From 131.22 to 288.